Albiglutide: A new GLP-1 analog for the treatment of type 2 diabetes

Expert Opinion on Biological Therapy

Volumn 10, Issue 5, 2010, Pages 801-806

  St Onge, Erin L ^a   Miller, Shannon A ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

Albiglutide; Albugon; GLP 1; Incretin; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; AVE 0010; CJC 1134 PC; EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; LY 2189265; METFORMIN; NN 9535; PIOGLITAZONE; PLACEBO; R 1583; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; AREA UNDER THE CURVE; BACKACHE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; GLYCEMIC CONTROL; HEMORRHAGIC HEPATITIS; HEPATITIS; HUMAN; HYPOGLYCEMIA; INFLUENZA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NECROTIZING HEPATITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SKIN MANIFESTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; TREATMENT OUTCOME;

EID: 77951100878     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.481281     Document Type: Review

References (35)

1. Number of people with diabetes increases to 24 million. Atlanta, GA: Centers for Disease Control and Prevention. 2008. Available from: http://www.cdc. gov/media/pressrel/2008/r080624.htm [Last accessed 27 March 2010]
2. American Association of Clinical Endocrinologists/American College of Endocrinology Glycemic Control Algorithm Consensus Panel. Glycemic control algorithm. Endocr Pract 2009;10(6):541-559
3. American Diabetes Association. Standards of Medical Care in Diabetes 2010. Diabetes Care 2010;33(Suppl 1):S11-61
4. McIntosh C, Demuth H, Pospisilik J, et al. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005;128:159-165
5. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93(12):4810-4817
6. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inibitors. Pharmacol Ther 2009;124:113-138
7. Defronzo R, Ratner R, Jan J, et al. Effects of Exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-1100
8. Buse JB, Henry RR, Hans J, et al. Effects of Exenatide (Exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-2635
9. Kendall DM, Riddle MC, Rosenstock JC, et al. Effects of Exenatide (Exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-1091
10. Zinman R, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-485
11. Vilsboll T. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lower and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007;30:1608-1610
12. Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
13. Garber A. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
14. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes [abstract 13-OR]. Program and abstracts of the 68th Scientific Sessions of the American Diabetes Association; 6 -- 10 June 2008; San Francisco, California
15. Nauck MA, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus(LEAD 2 study). Diabetes Care 2009;32:84-90
16. Russel-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes (LEAD 5) [abstract 536-P]. Program and abstracts of the 68th Scientific Sessions of the American Diabetes Association; 6 -- 10 June 2008; San Francisco, California
17. Victoza (liraglutide). EPAR summary for the public. London, UK: European Medicines Agency, 2009. Available from: http://www.ema. europa.eu/humandocs/ PDFs/EPAR/ victoza/H-1026-en1.pdf [Last accessed 27 March 2010]
18. Liraglutide (marketed as Victoza). Postmarket Drug Safety Information for Patients and Providers. Rockville, MD: US Food and Drug Administration, 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders/ucm198437.htm [Last accessed 27 March 2010]
19. Information for Healthcare Professionals: Exenatide (marketed as Byetta)--8/2008 Update. Postmarket Drug Safety Information for Patients and Providers. Rockville, MD: US Food and Drug Administration, 2008. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders/ucm124713.htm [Last accessed 27 March 2010]
20. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide the FDAs review of a new antidiabetic therapy. NEJM 2010;362(9):774-777
21. Lovshin J, Drucker D. A review of incretin-based therapies for type 2 diabetes treatment. Rev Endocrinol 2009:23-27
22. Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32(10):1880-1886
23. Baggio L, Huang Q, Brown T, Drucker D. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-2500
24. Bush M, Matthews J, DeBoever E, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in health subjects. Diabetes Obesity Metab 2009;11:498-505
25. Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25(12):3049-3057
26. Safety and efficacy study of albiglutide in type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT00849017?term=albiglutide&rank=2 [Last accessed 27 March 2010]
27. A study of the pharmacokinetics of albiglutide in normal and renally impaired subjects. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT00938158?term=albiglutide&rank=1 [Last accessed 27 March 2010]
28. A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT00838916?term=albiglutide&rank=7 [Last accessed 27 March 2010]
29. A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT00839527?term=albiglutide&rank=3 [Last accessed 27 March 2010]
30. Efficacy and safety of albiglutide in treatment of type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT00838903?term= albiglutide&rank=5 [Last accessed 27 March 2010]
31. Safety and efficacy of albiglutide in type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT00849056?term=albiglutide&rank=6 [Last accessed 27 March 2010]
32. A study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ ct2/show/NCT00976391? term=albiglutide&rank=4 [Last accessed 27 March 2010]
33. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2006;29(8):1963-1971
34. Nathan DM, Buse JB, Davidson MB, et al. Medical Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2009;32(1):193-203
35. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865